carfilzomib / Generic mfg. - LARVOL DELTA

Comparison of elranatamab's progression-free survival, duration of response, and overall survival from MagnetisMM-3 versus real-world external control arms: A subgroup analysis of China-predominant treatment regimens (ASH 2025) - P2 | "Two China-specific physician's choice of therapy (CSPCT) subgroups were created by identifying patients receiving the predominant treatment regimens in China from the identified COTA cohort (CSPCT1: DVd, D-VMP, DKd, IxaDd, DRd, DPd, DRVd, DVTd; CSPCT2: daratumumab + [either carfilzomib or bortezomib or ixazomib] + any non-IMiD). In unweighted analyses vs CSPCT2, ELRA was associated with longer PFS (mPFS, 17.25 vs 4.93 months; HR, 0.55; 95% CI, 0.34-0.89; P <.05), numerically longer OS (mOS, 24.61 vs 14.95 months; HR, 0.70; 95% CI, 0.46-1.08; P =.11), and longer DOR (mDOR, NR vs 4.70 months; HR, 0.17; 95% CI, 0.07-0.41; P <.05). Conclusions Among BCMA-naive patients with RRMM who resemble those from the MM-3 trial, patients treated with ELRA have better outcomes than patients using the predominant treatment regimens available in China."

Clinical • Real-world • Real-world evidence • Hematological Malignancies • Leukemia • Multiple Myeloma • Plasma Cell Leukemia

Plasma cell leukemia: A single institution review of cases (ASH 2025) - "For salvage therapies, 4 patients received DCEP, 2 received PACE-based regimens, 1 patient achieved remission while on teclistamab, one had delayed ASCT (with third line therapy), and one received CAR-T therapy...There was no statistically significant difference in PFS1 (p = 0.86) or OS (p = 0.57) between patients who received conventional chemotherapy and those treated with a daratumumab-based quadruplet induction regimen. Of note, the majority of patients that received these quadruplet regimens did not receive lenalidomide or carfilzomib for induction of PCL. Although the results of this retrospective study showed that there was no significant difference in PFS1 and OS based on induction regimens, some patients received suboptimal regimens due to various constraints including prior treatment regimens, comorbidities, socioeconomic factors, and variabilities in access to care. Despite therapeutic advances in MM, PFS and OS in patients with both pPCL and sPCL remains..."

Clinical • Review • Endocrine Disorders • Hematological Disorders • Hematological Malignancies • Leukemia • Metabolic Disorders • Multiple Myeloma • Nephrology • Plasma Cell Leukemia • Renal Disease • RB1

A lean thinking approach to improve efficiency in providing immune-chemotherapy injection in out-patient service: A pivotal study (ASH 2025) - "Thus, room A can be dedicated to longer infusion times (> 2 hours, like CHOP, ABVD, obinotuzumab etc), B room for intermediate therapies (30 min-2 hours, like carfilzomib, decitabine), room D for short therapies (less than 10 minutes, like bispecific antibodies, daratumumab, bortezomib), room C for device maintenance and blood drawing, obtaining a further NVT reduction to 57 minutes but a NVTp worsening to 48%...Based on these scenarios, we developed an integrated software solution with AI functionality based on the automation of infusion station assignment, eliminating the distinction by pathology and length of treatment, reducing the average patient waiting time to 13 minutes, the in-patient stay to 23 minutes for short-term therapies, such as daratumumab and bispecifics, and 45 minutes for intermediate therapies such as isatuximab infusion. Conclusions Our approach proposes leveraging existing infrastructure resources, particularly infusion chairs, which are often..."

Clinical • Hematological Malignancies • Oncology

Comprehensive cost analysis of 4th line + therapies for relapsed/refractory multiple myeloma in Germany: Drug, co-medication, and office-based treatment perspective (ASH 2025) - "Whilst there is no official myeloma registry in Germany, treatments we considered were reimbursable combination therapies frequently used in the 4 th line treatment of RRMM in Germany in 2023, containing: carfilzomib, daratumumab, elotuzumab, melflufen, selinexor, talquetamab and teclistamab, and newly approved therapeutic options like elranatamab, along with evidence-based recommendations regarding premedication, comedication, and mandatory prophylaxis of treatment-related adverse events, as outlined in the Summary of Product Characteristics (SmPC) and published literature... Costs for myeloma drugs and combinations show a broad variation, from 88.863€ for Elotuzumab/Revlimid/Dexamethasone (ERd), to 178.850€ for talquetamab treatment. The second lowest in terms of annual costs was melflufen with 106.839€, followed by Elotuzumab/Pomalidomide/Dexamethasone (EPd):119.301€, teclistamab: 124.626€, Selinexor/Dexamethasone (Sd): 129.976€, elranatamab: 146.706€ and..."

Cost-analysis • HEOR • Hematological Malignancies • Multiple Myeloma

High risk MDS in the wke of anti-BCMA CART therapy in refractory multiple myeloma. (ASH 2025) - "Case Report We present the case of a female patient diagnosed with IgG multiple myeloma in 2015, initially treated with induction chemotherapy using lenalidomide, bortezomib, and dexamethasone (RVD), followed by autologous HSCT...She subsequently progressed on a combination of daratumumab, lenalidomide, and dexamethasone. Further disease progression occurred on a regimen of ixazomib, pomalidomide, and dexamethasone. She then achieved a temporary response to carfilzomib, lenalidomide, and dexamethasone, followed by a second autologous HSCT, but relapsed again after approximately one year of maintenance therapy...While this association warrants further investigation, it emphasizes the need for ongoing observation of patients who have received CAR T-cell therapy. Future studies should aim to clarify the potential mechanistic links, including clonal evolution, selective pressures imposed by immunotherapy, and the contribution of prior cytotoxic exposures."

IO biomarker • Acute Lymphocytic Leukemia • B Cell Lymphoma • Bone Marrow Transplantation • Cardiomyopathy • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Multiple Myeloma • Myelodysplastic Syndrome • Non-Hodgkin’s Lymphoma • TP53

Real-world treatment landscape after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myeloma: An international Study (ASH 2025) - "Novel BCMA-targeted therapies, such as CAR T-cells (cilta-cel from 2nd line, ide-cel from 3rd line) and bispecific T-cell engagers (e.g., teclistamab, elranatamab from 4th line), have become new standards of care...Abbreviations: K=carfilzomib; E=elotuzumab; Pom=pomalidomide; d=dexamethasone; Isa=isatuximab; F=panobinostat; R=lenalidomide; Tec=teclistamab; X=selinexor; Elra=elranatamab; Belamaf=belantamab mafodotin; Ixa=ixazomib... This real-world study of 100 MM patients relapsing after anti-BCMA CAR T-cell treatment shows that 91% were in their 4th or 5th line of therapy. A large majority were triple-class exposed, and 52% were lenalidomide-refractory. In the absence of a clear standard of care, common treatments were identified: elotuzumab- and isatuximab-based regimens in the 3rd line; teclistamab and elotuzumab-based options in the 4th line; and teclistamab, elranatamab, and belantamab mafodotin in the 5th line."

CAR T-Cell Therapy • Clinical • HEOR • Real-world • Real-world evidence • Cardiovascular • Diabetes • Dyslipidemia • Hematological Malignancies • Hypertension • Metabolic Disorders • Multiple Myeloma • Renal Disease

Real-world outcomes and toxicities of elranatamab (ELRA) in relapsed/refractory multiple myeloma: A retrospective analysis using the trinetx global health research network. (ASH 2025) - "Treatment exposure patterns indicated a heavily pretreated, triple-class refractory population: proteasome inhibitors (bortezomib 61%, carfilzomib 47%), IMiDs (lenalidomide 67%, pomalidomide 69%), and anti-CD38 monoclonal antibodies (daratumumab 67%). Additional therapies included CAR T-cell therapy (8%), autologous stem cell transplant (23%), Belantamab mafodotin (8%), Talquetamab (10%), and Teclistamab (8%)...Tocilizumab was used in 21% of patients... In comparison to the MagnetisMM-3 trial, this real-world analysis confirms the manageable immune toxicity profile of ELRA, with similarly low rates of grade ≥3 CRS and ICANS. However, the higher 6-month mortality (22.6%) observed in this cohort may reflect broader patient inclusion, including those with significant comorbidities and prior BCMA-directed therapies. Hematologic and infectious toxicities were substantial, reinforcing the need for enhanced monitoring and supportive care strategies in routine clinical use."

Real-world • Real-world evidence • Retrospective data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Influenza • Leukemia • Multiple Myeloma • Nephrology • Neutropenia • Plasma Cell Leukemia • Pneumonia • Respiratory Diseases • Septic Shock • Thrombocytopenia

Real-world outcomes and toxicities of talquetamab (Tal) in Relapsed/Refractory multiple myeloma (RRMM): A retrospective analysis using the trinetx global health research network. (ASH 2025) - "Treatment patterns reflected a triple-class refractory population, with high prior exposure to proteasome inhibitors (bortezomib 52%, carfilzomib 48%), IMiDs (lenalidomide 66%, pomalidomide 63%), and anti-CD38 antibodies (daratumumab 51%). Additionally, 35% had received CAR T-cell therapy, 39% underwent ASCT, 24% were treated with Teclistamab, and extramedullary disease and plasma cell leukemia were reported in 11% and 13% of patients, respectively...Grade ≥3 CRS and ICANS occurred in <10 patients each (2.4%), and 24% received tocilizumab for CRS... In this large, real-world cohort, Talquetamab demonstrated favorable short-term survival and a manageable safety profile, consistent with clinical trial data. The higher mortality observed may reflect the heavily pretreated, triple-class refractory population with advanced disease features and comorbidities often seen in real-world settings. Hematologic toxicities remained significant, while lower observed rates of..."

Real-world • Real-world evidence • Retrospective data • Dermatology • Multiple Myeloma • Neutropenia • Plasma Cell Leukemia • Thrombocytopenia

Preliminary analysis of a single-center study on chidamide combined with ICD regimen in bortezomib-exposed relapsed/refractory multiple myeloma patients (ASH 2025) - P2 | "Thus, we aimed to evaluate the efficacy and safety of chidamide combined with the ICD regimen (ixazomib, cyclophosphamide, dexamethasone) in RRMM patients exposed to bortezomib...All patients had received a median of 2 prior lines (range: 1–6), with 100% exposed to bortezomib and 90.9% to lenalidomide, 18.2% to ixazomib, 18.2% to carfilzomib, and 18.2% to daratumumab... Preliminary results demonstrate promising clinical efficacy and manageable safety of chidamide combined with ICD in RRMM patients double-exposed to bortezomib and lenalidomide. Further validation with larger cohorts and longer follow-up is warranted."

Clinical • Hematological Malignancies • Hepatology • Infectious Disease • Liver Failure • Multiple Myeloma • Pneumonia • Respiratory Diseases

Selinexor-based regimens in triple-class exposed or refractory multiple myeloma: A real-world analysis of efficacy and safety in 18 patients (ASH 2025) - "Treatment regimens included selinexor (40–60 mg/week) combined with the KPD regimen (carfilzomib, pomalidomide, dexamethasone) in 6/18 (33.3%) patients; other combinations comprised cytotoxic drugs, aponermin, daratumumab, and venetoclax. Selinexor-based regimens demonstrate clinically meaningful efficacy (ORR 66.7%, median PFS 10.9 months) and a manageable safety profile in heavily pretreated TCE/TCR RRMM patients. These findings support its use as a viable salvage therapy. Further validation through larger prospective trials is warranted to confirm these results."

Clinical • Real-world • Real-world evidence • Multiple Myeloma • Nephrology • Neutropenia • Plasma Cell Leukemia • Plasmacytoma • Renal Disease • Thrombocytopenia • XPO1

Real-world safety and efficacy of aponermin and selinexor-based regimens in patients with multiple myeloma (ASH 2025) - "Treatment regimens predominantly consisted of Apo+selinexor+dexamethasone (65.38%), with other combinations including Apo + daratumumab + selinexor + dexamethasone (11.54%), Apo + selinexor + carfilzomib + pomalidomide + dexamethasone (7.69%), Apo + selinexor + pomalidomide + dexamethasone (7.69%), Apo + selinexor + carfilzomib + dexamethasone (3.85%) and Apo + selinexor + cyclophosphamide + dexamethasone (3.85%). The median age was 66 years (range 29-82), with 65.38% male patients. R-ISS staging showed 11.54% stage I, 42.31% stage II, and 30.77% stage III. High-risk cytogenetic abnormalities included 1q21 gain/amplification (50.00%), t(4; 14) (19.23%), 17p deletion (15.38%) and double-hit HRCA (26.92%)."

Clinical • Real-world • Real-world evidence • Constipation • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Leukemia • Leukopenia • Lymphoma • Multiple Myeloma • Thrombocytopenia

Real-world safety and efficacy of aponermin and daratumumab-based regimens in patients with multiple myeloma (ASH 2025) - "Treatment regimens consisted of aponermin combined with daratumumab and various backbone therapies: dexamethasone (35.71%), selinexor-dexamethasone (28.57%), bortezomib-dexamethasone (14.29%), lenalidomide-dexamethasone (7.14%), cyclophosphamide-dexamethasone (7.14%), and carfilzomib-dexamethasone (7.14%). No hepatotoxicity was observed throughout the treatment period. Real-world data demonstrate that aponermin and daratumumab-based regimens exhibit promising efficacy and favorable safety profiles in MM patients, particularly in heavily pretreated RRMM patients, offering a potential new treatment option for this challenging population."

Clinical • IO biomarker • Real-world • Real-world evidence • Constipation • Gastroenterology • Gastrointestinal Disorder • Lymphoma • Multiple Myeloma • Thrombocytopenia

Clinical efficacy and safety of daratumumab-carfilzomib based therapy in newly diagnosed multiple myeloma: A retrospective cohort analysis (ASH 2025) - "The DK-based regimens (DKd; DKBd; DKCd; DKRd) — combining daratumumab, carfilzomib, dexamethasone ± bendamustine, cyclophosphamide, or lenalidomide — were administered in 28-day cycles (≥2 cycles). DK-based regimens achieved high effectivity in patients with NDMM not undergoing ASCT, including those with EMD. Efficacy improved with prolonged treatment. The combination of carfilzomib and daratuzumab aligns with published data, confirming feasibility and effectiveness."

Retrospective data • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension • Multiple Myeloma • Neutropenia • Pulmonary Disease

Early intervention in smoldering multiple myeloma: A systematic review of comparative prospective trials (ASH 2025) - "Two studies were phase I/II trials, one comparing the use of dose-escalated multipeptide PVX-410 vaccine +/- lenalidomide (R) in SMM patients, and the other comparing dose-escalated anakinra +/-Lenalidomide/dexamethasone (Rd)...Two studies were phase II RCTs; one compared Rd +/- Carfilzomib (K) in 58 high-risk SMM patients, with statistically significantly higher 3-year PFS in KRd of 94% versus Rd of 40%; p<0.001, across a median follow-up period of 34 months...The second phase II RCT included 20 intermediate- and high-risk SMM patients treated with Iberdomide (I) +/- d, with ORR of 84.6% versus 80% in the Id versus I group...One phase III RCT compared zoledronic acid +/- thalidomide in a total of 68 SMM patients, with a median TTP of 2.4 versus 1.2 years, 1-year PFS of 85% versus 55%, and 1-year ORR of 37% versus no confirmed response during the median follow-up of 5.9 years... Preliminary evidence from comparative trials suggests that early treatment of..."

Clinical • Review • Hematological Malignancies • Multiple Myeloma • Smoldering Multiple Myeloma

Efficacy and safety of aponermin combined with immunomodulators in relapsed/refractory multiple myeloma (ASH 2025) - "Treatment regimens included aponermin plus carfilzomib, thalidomide, and dexamethasone (Apo-KTd); aponermin plus carfilzomib, pomalidomide, and dexamethasone (Apo-KPd); aponermin plus pomalidomide and dexamethasone (Apo-Pd); aponermin plus thalidomide and dexamethasone (Apo-Td), and other combination therapies based on aponermin. Conclusion Aponermin combined with immunomodulators demonstrates good tolerability and definite efficacy for RRMM, especially for long-term treatment. Patients with high-risk cytogenetics, extramedullary lesions, and those who have failed multiple lines of treatment can still benefit."

Clinical • Immunomodulating • IO biomarker • Hematological Malignancies • Multiple Myeloma

Once-weekly carfilzomib (56 mg/m²), pomalidomide, and dexamethasone (K56Pd) in patients with first-relapsed multiple myeloma: a Multicenter, prospective, Real-world evidence from China (ASH 2025) - "Prior therapies included bortezomib (19.4% refractory), lenalidomide (90.3% refractory), and anti-CD38 antibodies (3.2% refractory); 6 (19.4%) were dual-refractory to bortezomib/lenalidomide, and 1 (3.2%) triple-refractory (bortezomib/lenalidomide/anti-CD38). The weekly K56Pd regimen demonstrated meaningful clinical benefits and manageable safety in patients with MM at first relapse in real-world settings."

Clinical • HEOR • Real-world • Real-world evidence • Bone Marrow Transplantation • Hematological Disorders • Hematological Malignancies • Hypertension • Infectious Disease • Leukemia • Leukopenia • Lymphoma • Multiple Myeloma • Thrombocytopenia

Indirect treatment comparison of belantamab mafodotin + pomalidomide + dexamethasone versus comparator regimens in lenalidomide-exposed relapsed/refractory multiple myeloma: A network meta-analysis (ASH 2025) - P3 | " In the len-exposed population, the PFS network comprised 8 RCTs (including DREAMM-8) with comparator regimens: carfilzomib + dexamethasone (Kd), Kd + daratumumab (DKd), isatuximab + carfilzomib + dexamethasone (IsaKd), bortezomib + dexamethasone (Vd), DVd, PVd, and selinexor + Vd (SVd). In the absence of head-to-head randomized controlled trials, these ITC data suggested a high probability that PFS consistently favored BPd vs comparator regimens of interest in len-exposed patients with RRMM, with consistent findings in the IPTW analysis reducing uncertainty in the base-case NMA findings."

Retrospective data • Hematological Malignancies • Multiple Myeloma

Anti-CD38-based quadruplet versus triplet induction regimens in transplant-ineligible newly diagnosed multiple myeloma: A systematic review and meta-analysis (ASH 2025) - "Introduction Triplet induction therapy with either daratumumab, lenalidomide, and dexamethasone (D-Rd) or bortezomib, lenalidomide, and dexamethasone (VRd) has long been the standard of care for transplant-ineligible patients with newly diagnosed multiple myeloma (TIE-NDMM)...The quadruplet regimens comprised an anti-CD38 monoclonal antibody (daratumumab or isatuximab), a proteasome inhibitor (bortezomib or carfilzomib), an immunomodulatory drug (lenalidomide) or alkylator (melphalan or cyclophosphamide), and a corticosteroid...While quadruplet regimens were associated with higher rates of SAEs and grade 3-4 infections, no significant differences were observed in the rates of grade 3-4 neutropenia or thrombocytopenia. Careful patient selection is essential to optimize outcomes and mitigate treatment-related toxicity."

Retrospective data • Review • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Thrombocytopenia • Transplantation

Peripheral blood stem cell collection for patients with multiple myeloma undergoing autologous transplant after quadruplet induction (ASH 2025) - "Background: In recent years, quadruplet induction regimens, including daratumumab, bortezomib, lenalidomide and dexamethasone (D-VRD) and daratumumab, carfilzomib, lenalidomide and dexamethasone (D-KRD) are increasingly used for patients with newly diagnosed multiple myeloma (MM)...The majority of patients in both CD34 groups (n=123, 88%) received GCSF+plerixafor for stem cell mobilization. Six patients received chemo-mobilization with cyclophosphamide, all in the high CD34 group... In our cohort, approximately one in six patients who received quadruplet induction had suboptimal PBSC collection prior to autoHCT, which was more commonly seen in older patients. The number of induction cycles and lenalidomide dose during induction did not significantly impact the yield of stem cell collection. A lower CD34 collection did not adversely impact the engraftment, response rates or survival outcomes."

Clinical • Hematological Malignancies • Multiple Myeloma • Transplantation • CD34

A real-world study on first-line early switch to kpd regimen in the treatment of multiple myeloma patients with suboptimal induction efficacy or intolerance (ASH 2025) - " Patients from 12medical centers in Henan Province who did not achieve very good partial response (VGPR) after two cycles of first-line induction therapy (VRD [bortezomib + lenalidomide + dexamethasone], VD [bortezomib + dexamethasone], or VPD [bortezomib + pomalidomide + dexamethasone]) or experienced grade ≥2 adverse events (CTCAE criteria) were switched to the KPD regimen(Carfilzomib [20/27 mg/m² on days 1, 2, 8, 9, 15, and 16], pomalidomide [4 mg on days 1-21] and dexamethasone [20 mg on days 1, 2, 8, 9, 15, and 16]). This multicenter real-world observational study suggests that multiple myeloma patients with suboptimal efficacy or intolerance to first-line induction therapy who switch to the KPd regimen early have a high response rate and achieve deeper remission. No new adverse events were observed compared with clinical studies."

Clinical • Real-world • Real-world evidence • Cardiovascular • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Thrombocytopenia • CD34

Real-world stratified treatment strategies in transplant-eligible newly diagnosed multiple myeloma: A multicohort study (ASH 2025) - "Methods Real-world cohorts from First Affiliated Hospital of Sun Yat-sen University (2024–2025): - UHiR cohort (n=26): Dara-KAD (daratumumab, carfilzomib, liposomal doxorubicin, dexamethasone) induction → tandem ASCT → carfilzomib/pomalidomide maintenance. Mobilization remained feasible across all cohorts with proactive plerixafor use. Real-world evidence supports risk-adapted induction, transplantation, and mobilization strategies."

Clinical • Real-world • Real-world evidence • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Neutropenia • Transplantation • CD34

Aponermin-based regimen as bridging therapy prior to CAR-T cell therapy for relapsed/refractory multiple myeloma (ASH 2025) - "He received induction therapy with the PAD regimen (bortezomib, liposomal doxorubicin, dexamethasone) and DKd regimen (daratumumab, carfilzomib, dexamethasone), achieving a Very Good Partial Response (VGPR)...Maintenance therapy with the KP regimen (carfilzomib, pomalidomide) was administered, during which surveillance studies showed minimal residual disease (MRD) negativity by bone marrow flow cytometry and negative serum and urine immunofixation electrophoresis...Bridging therapy was initiated the following day (February 23, 2025) with Aponermin (10mg/kg on Days 1-5), Selinexor (40mg once weekly), and dexamethasone (20mg once weekly)...The regimen did not adversely impact hematologic recovery following CAR-T cell infusion, and cytokine release syndrome (CRS) was mild and manageable. For patients with triple-class refractory (TCR) or penta-drug refractory multiple myeloma undergoing CAR-T cell therapy, Aponermin-based regimen represents a viable and well-tolerated..."

CAR T-Cell Therapy • Bone Marrow Transplantation • Hematological Malignancies • Inflammation • Multiple Myeloma

Safety and efficacy of carfilzomib-based combinations in relapsed/refractory multiple myeloma patients in a real-world Setting : Results of a french single academic center retrospective study. (ASH 2025) - "All patients had been exposed to IMiDs (lenalidomide, pomalidomide, thalidomide), 89% to proteasome inhibitors (bortezomib, carfilzomib, ixazomib), and 64% to anti-CD38 monoclonal antibodies (daratumumab, isatuximab). Initial weekly dosing of K followed by spacing out infusions in responding patients led to better tolerance. Currently, K-based combinations also represent interesting options as bridging therapy to CAR T-cells therapies."

Real-world • Real-world evidence • Retrospective data • Cardiovascular • Congestive Heart Failure • Coronary Artery Disease • Gastrointestinal Disorder • Heart Failure • Hematological Malignancies • Hypertension • Multiple Myeloma

Real-world efficacy and safety of carfilzomib-based combination regimens in patients with multiple myeloma (ASH 2025) - "Only 3 patients were newly diagnosed MM, among the remaining 100 patients, 99 (99.0%) had prior exposure to bortezomib, 41.0% had received prior anti-CD38 monoclonal antibody (mAb), and 10 patients had undergone prior autologous stem cell transplantation (ASCT)...16 (15.5%) patients received carfilzomib and dexamethasone (Kd) based therapy with or without anti-CD38 mAb, 46 (44.7%) received Kd combined with an immunomodulatory agent (IMiD) with or without anti-CD38 mAb, 33 (32.0%) received Kd combined with chemotherapy with or without anti-CD38 mAb, and 8 (7.8%) received Kd combined with other regimens...Among these, two patients experienced grade ≥3 CVAEs, one developed atrial fibrillation, which improved following amiodarone administration, and the other experienced heart failure, which was alleviated with diuretic and coronary vasodilator therapy...Conclusion Carfilzomib-based combination regimens demonstrated encouraging efficacy and manageable safety profiles in..."

Clinical • IO biomarker • Real-world • Real-world effectiveness • Real-world evidence • Acute Kidney Injury • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Dermatitis • Dermatology • Heart Failure • Hypertension • Immunology • Infectious Disease • Leukopenia • Multiple Myeloma • Nephrology • Pulmonary Embolism • Renal Disease • Respiratory Diseases • Thrombocytopenia

From fit to frail: Effectiveness and safety of fixed-dose carfilzomib in the treatment of multiple myeloma – a single-center, real world evidence in China (ASH 2025) - "Two cohorts: (1) first-line conversion—switched within ≤4 bortezomib cycles owing to intolerance or poor response; (2) relapse/refractory—progressed after ≥2 prior lines. Notably, the 60 mg weekly regimen resulted in functional reversal in 86.7% of frail patients and was well tolerated. Further expansion of the sample size is warranted for validation of these findings."

Clinical • HEOR • Real-world • Real-world evidence • Cardiovascular • Infectious Disease • Multiple Myeloma • Neutropenia • Thrombocytopenia